<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B5D5FB3A-091F-468E-A425-762A6EF3757F"><gtr:id>B5D5FB3A-091F-468E-A425-762A6EF3757F</gtr:id><gtr:name>Edinburgh Instruments Ltd</gtr:name><gtr:address><gtr:line1>10 Heriot-Watt Res Park</gtr:line1><gtr:line2>Riccarton</gtr:line2><gtr:line4>Currie</gtr:line4><gtr:line5>Midlothian</gtr:line5><gtr:postCode>EH14 4AP</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6498342E-F5B8-46DC-99E3-9899442C9536"><gtr:id>6498342E-F5B8-46DC-99E3-9899442C9536</gtr:id><gtr:name>Perkin Elmer</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E5A82D2C-5AD4-488A-ACFF-566345A5D6DA"><gtr:id>E5A82D2C-5AD4-488A-ACFF-566345A5D6DA</gtr:id><gtr:name>Heriot-Watt University</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Riccarton</gtr:line2><gtr:line3>Ricarton</gtr:line3><gtr:line4>Currie</gtr:line4><gtr:postCode>EH14 4AS</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7F576372-7832-4E5D-AAEE-C760CDB7F9B3"><gtr:id>7F576372-7832-4E5D-AAEE-C760CDB7F9B3</gtr:id><gtr:name>Sequenom</gtr:name><gtr:address><gtr:line1>Sequenom</gtr:line1><gtr:line2>3595 John Hopkins Court</gtr:line2><gtr:postCode>CA 92121-1</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1AB6C9A-B724-4044-ABA4-89C61A7754CD"><gtr:id>D1AB6C9A-B724-4044-ABA4-89C61A7754CD</gtr:id><gtr:name>Axis-Shield</gtr:name><gtr:address><gtr:line1>Luna Place</gtr:line1><gtr:line2>Dundee Technology Park</gtr:line2><gtr:postCode>DD2 1XA</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850"><gtr:id>5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850</gtr:id><gtr:name>University of Strathclyde</gtr:name><gtr:address><gtr:line1>16 Richmond Street</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G1 1XQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FFC47743-F91A-43B7-8B4F-67FC9D0E0600"><gtr:id>FFC47743-F91A-43B7-8B4F-67FC9D0E0600</gtr:id><gtr:name>M?lnlycke Healthcare Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B5D5FB3A-091F-468E-A425-762A6EF3757F"><gtr:id>B5D5FB3A-091F-468E-A425-762A6EF3757F</gtr:id><gtr:name>Edinburgh Instruments Ltd</gtr:name><gtr:address><gtr:line1>10 Heriot-Watt Res Park</gtr:line1><gtr:line2>Riccarton</gtr:line2><gtr:line4>Currie</gtr:line4><gtr:line5>Midlothian</gtr:line5><gtr:postCode>EH14 4AP</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6498342E-F5B8-46DC-99E3-9899442C9536"><gtr:id>6498342E-F5B8-46DC-99E3-9899442C9536</gtr:id><gtr:name>Perkin Elmer</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E5A82D2C-5AD4-488A-ACFF-566345A5D6DA"><gtr:id>E5A82D2C-5AD4-488A-ACFF-566345A5D6DA</gtr:id><gtr:name>Heriot-Watt University</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Riccarton</gtr:line2><gtr:line3>Ricarton</gtr:line3><gtr:line4>Currie</gtr:line4><gtr:postCode>EH14 4AS</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7F576372-7832-4E5D-AAEE-C760CDB7F9B3"><gtr:id>7F576372-7832-4E5D-AAEE-C760CDB7F9B3</gtr:id><gtr:name>Sequenom</gtr:name><gtr:address><gtr:line1>Sequenom</gtr:line1><gtr:line2>3595 John Hopkins Court</gtr:line2><gtr:postCode>CA 92121-1</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1AB6C9A-B724-4044-ABA4-89C61A7754CD"><gtr:id>D1AB6C9A-B724-4044-ABA4-89C61A7754CD</gtr:id><gtr:name>Axis-Shield</gtr:name><gtr:address><gtr:line1>Luna Place</gtr:line1><gtr:line2>Dundee Technology Park</gtr:line2><gtr:postCode>DD2 1XA</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850"><gtr:id>5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850</gtr:id><gtr:name>University of Strathclyde</gtr:name><gtr:address><gtr:line1>16 Richmond Street</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G1 1XQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FFC47743-F91A-43B7-8B4F-67FC9D0E0600"><gtr:id>FFC47743-F91A-43B7-8B4F-67FC9D0E0600</gtr:id><gtr:name>M?lnlycke Healthcare Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/43624727-2D66-49AE-8923-426DD4CDD141"><gtr:id>43624727-2D66-49AE-8923-426DD4CDD141</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Seckl</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_12014"><gtr:id>6CD82414-2859-4C11-B0FE-F577F99C234B</gtr:id><gtr:title>Confidence in Concept 2012 - Edinburgh</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_12014</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2014-03-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-09-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>700000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Perkin Elmer</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>CiC fetaSAFE</gtr:description><gtr:id>0F3A9190-B965-44E9-A73C-1E1D171C7F8F</gtr:id><gtr:impact>materials are being provided by partner for evaluation in the device to bench mark to current technology</gtr:impact><gtr:outcomeId>545b5851a0adf2.73235800-1</gtr:outcomeId><gtr:partnerContribution>Perkin Elmer hare developing tests in this arena and are interested in techniques that can increase the opportunity for low fetal DNA samples to be suitable for assay</gtr:partnerContribution><gtr:piContribution>We have developed a system for the sample concentration and purification of fetal DNA from maternal blood</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Axis-Shield</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MicroBRT CiC</gtr:description><gtr:id>C687F11C-9DD7-4644-B057-F9590147E3F7</gtr:id><gtr:impact>The partners provided considerable input to the Target Product Profile and the final milestone of the CiC. Discussions are on going regarding next stage of development. 
A student ship has been initiated on the background science.</gtr:impact><gtr:outcomeId>545a26ca3b3069.33094154-1</gtr:outcomeId><gtr:partnerContribution>Designing and developing the microfluidic sample processing system.</gtr:partnerContribution><gtr:piContribution>The MicroBRT project seeks to identify the micro RNA signature from treatment of bacterial pathogens by antibiotics and organise the purification of the analyte using a microfluidic system.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Heriot-Watt University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Chemistry</gtr:department><gtr:description>CiC Catanostics</gtr:description><gtr:id>966E5892-9052-469F-A6FC-6996B7F74F4A</gtr:id><gtr:impact>Multi-disciplinary academic medical and industrial product development project.</gtr:impact><gtr:outcomeId>J9EzQUnUVux-1</gtr:outcomeId><gtr:partnerContribution>These SMEs have themselves have committed ?1.4M cash</gtr:partnerContribution><gtr:piContribution>Catanostics EU &amp;amp; HWU has obtained support entitled 'CATACURE' 

The total project is ?2.7M and has 5 partners across Europe; Sweden and Denmark (opthalmic hospitals), Denmark (optical filters), UK (Edinburgh Biosciences - cataract monitoring is becoming a major part of EBS business), Germany (instrument manufacture). These SMEs have themselves have committed ?1.4M cash investment which took a lot of negotiation! Bal Dhillon will Chair the Steering group for this project, keeping a UoE hand in it. The project will deliver several prototype instruments that will provide the appropriate laser illumination for therapy for trials in the opthalmic hospitals and Asia. This ought to be a strong output for the CiC award.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Edinburgh Instruments Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CiC EPDD 002 CATANOSTICS</gtr:description><gtr:id>8ABCE857-0FEF-4606-AFFB-EDA683AD7BCF</gtr:id><gtr:impact>Project complete all miles met.</gtr:impact><gtr:outcomeId>AYZQX1YK5v6-1</gtr:outcomeId><gtr:partnerContribution>partner is providing very valuable hardware</gtr:partnerContribution><gtr:piContribution>we are building the device</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>M?lnlycke Healthcare Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>M?lnlycke Health Care?Scotland (MHC-S)</gtr:department><gtr:description>CiC EPDD 011 mirPOC - detection of miRNAs indicating drug-induced liver injury at point-of-care.</gtr:description><gtr:id>FE9B60A8-569D-4A5C-A8F1-2E8902D2C1DE</gtr:id><gtr:impact>early in CiC</gtr:impact><gtr:outcomeId>GLL2BzJc2ZX-1</gtr:outcomeId><gtr:partnerContribution>Partners are contributing system and domain expertise</gtr:partnerContribution><gtr:piContribution>We are bringing analyte to distinguish disease (paracetamol-induced liver injury) from control (paracetamol overdose without any injury). Final milestone will deliver a Test can distinguish healthy from diseased</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Strathclyde</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Biomedical Engineering</gtr:department><gtr:description>CiC EPDD 010 A portable integrated device for organ recovery from donors after circulatory death under normothermic conditions.</gtr:description><gtr:id>E83DD285-C805-495E-8755-4DA559A61CB0</gtr:id><gtr:impact>too early in CiC</gtr:impact><gtr:outcomeId>PNXUgJgJDAS-1</gtr:outcomeId><gtr:partnerContribution>Partners are providing the oxygenation system</gtr:partnerContribution><gtr:piContribution>we are providing the portable device</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sequenom</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>CiC fetaSAFE</gtr:description><gtr:id>10AB2B7E-03BE-4ADA-96EF-43C53DB223FB</gtr:id><gtr:impact>test data not available yet</gtr:impact><gtr:outcomeId>545b597158b8f3.15183185-1</gtr:outcomeId><gtr:partnerContribution>Sequenom are the world leaders in fetal DNA testing and are engaged in advising and providing bench marking samples for evaluation in the microfluidics technology.</gtr:partnerContribution><gtr:piContribution>The fetaSAFE team have developed a sample processing device for improving the success rate and potentially lowering the cost barriers to analysis of fetal DNA in maternal circulation.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2700000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Competitiveness and Innovation Framework Programme (CIP)</gtr:department><gtr:description>CATACURE ICT Policy Support Programme</gtr:description><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>6210885</gtr:fundingRef><gtr:id>87C70B1A-7E7D-4981-81D8-4773C7FD045B</gtr:id><gtr:outcomeId>54590b0dc3c199.02829594</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>127000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CiC personalised voices for patients with MND</gtr:description><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:id>94892AAF-F920-40A9-AAB5-898BEC76489C</gtr:id><gtr:outcomeId>545b6ccf357535.73900721</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CiC 2012 (hepatic vascular catheter)</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>NHS Scotland</gtr:fundingOrg><gtr:id>1133B859-3879-47DE-A8E0-9F2BA07BF4E3</gtr:id><gtr:outcomeId>56df018da98dd7.22085333</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>44000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Institutional Strategic Support Fund</gtr:department><gtr:description>CiC2012 (Steroids) WT-ISSF2 funding</gtr:description><gtr:end>2026-05-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>X00000294</gtr:fundingRef><gtr:id>E1E37622-D46C-4B6D-91AE-66E40AAA9288</gtr:id><gtr:outcomeId>56deba5c5d6fb7.42384020</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>104000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CiC 2012 (Steroids)</gtr:description><gtr:end>2021-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>47C1D459-9651-43B8-BE22-F8E48451251D</gtr:id><gtr:outcomeId>56debe069efb24.96682179</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Moray Trust</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Moray Council</gtr:fundingOrg><gtr:id>493C31CE-1BF1-4B43-9A6C-1C12E647D17D</gtr:id><gtr:outcomeId>58c6bf049c9108.73037273</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CiC 2012 (personalised voices)</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>Digital Health Institute (DHI)</gtr:fundingOrg><gtr:id>52C5C8C8-3D04-4474-AB90-61E00015DAB4</gtr:id><gtr:outcomeId>56df006826ebe1.27052278</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>220883</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CiC 2012 (fetal diagnostic)</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Chief Scientist Office (CSO)</gtr:fundingOrg><gtr:id>F925B6DD-5D77-4223-A142-4C5A77B3E9CA</gtr:id><gtr:outcomeId>56dee97fe4b678.16903473</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>370000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CiC TissueStik</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Technology Strategy Board (TSB)</gtr:fundingOrg><gtr:id>B2A39E59-E9B5-47C1-95D0-EAC12AAB99F9</gtr:id><gtr:outcomeId>545b742ec0f5f6.22306261</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>108000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CiC 2012 (fetal diagnostic)</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Medical Research Scotland</gtr:fundingOrg><gtr:id>2F5F919B-5D96-4194-BB6E-EEF9E82F6EB9</gtr:id><gtr:outcomeId>56deeae78c3953.33627502</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>850000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Bloomsbury Centre</gtr:department><gtr:description>Multiuser Equipment Grant (Steroids)</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>FA75D6B7-03F5-49C3-9F54-DEF1704BF42C</gtr:id><gtr:outcomeId>58c6c0d249daa0.57273753</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2500</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>CiC 2012 (fetal diagnostic)</gtr:description><gtr:end>2020-06-02</gtr:end><gtr:fundingOrg>German Academic Exchange Service (DAAD)</gtr:fundingOrg><gtr:id>2E194A4A-3AF5-42A5-A29C-50E138346F5A</gtr:id><gtr:outcomeId>56deebb95905e3.66836450</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2500</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>CiC 2012 (fetal diagnostic)</gtr:description><gtr:end>2020-06-02</gtr:end><gtr:fundingOrg>German Academic Exchange Service (DAAD)</gtr:fundingOrg><gtr:id>9C81E4AA-063D-40B9-9A25-8FD01181FB6E</gtr:id><gtr:outcomeId>56deebbf62f330.87248946</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CiC2012 (Steriods)</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>British Mass Spectrometry Society</gtr:fundingOrg><gtr:id>4F8F1A2B-2D02-4F27-BBC4-0BBFA7A0E789</gtr:id><gtr:outcomeId>56debc1fcc5257.84557454</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>108000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CiC 2012 (micro BRT)</gtr:description><gtr:end>2024-09-02</gtr:end><gtr:fundingOrg>Medical Research Scotland</gtr:fundingOrg><gtr:id>BD42F2FA-1ED0-4287-9753-07A4308D77AC</gtr:id><gtr:outcomeId>56defe9ce8a625.41187932</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CiC 2012 (fetal diagnostic)</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Carnegie Trust</gtr:fundingOrg><gtr:id>EC823C2E-BD61-4815-95BF-F74276E229CF</gtr:id><gtr:outcomeId>56deea501f6ed8.87477426</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CiC A device for label free purification of viable cells for therapy</gtr:description><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>FEAFE178-EA02-4B22-A51B-FC1BEB93DBB6</gtr:id><gtr:outcomeId>545a774d281904.57214780</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>14000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CiC 20012 (steriods)</gtr:description><gtr:end>2023-03-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>66CA32E1-3AB3-42F0-98EC-F32E44B82F2E</gtr:id><gtr:outcomeId>56debcfe7d82c1.66240666</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>an instrument using a 315nm-LED and interference filter provides a safe light for detection of cataracts based on modification of the non tryptophan 430nm band generating an optical excitation 310-320nm range. This will provide early detection of cataracts and a quantitative measure of change by deterioration or therapy.</gtr:description><gtr:grantRef>MC_PC_12014</gtr:grantRef><gtr:id>5EE8DF46-4DAD-469F-B662-3D0B063A8994</gtr:id><gtr:impact>The EUR2.7M grant</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>54591c3835e5f0.04149643</gtr:outcomeId><gtr:patentId>UK 132313.03</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>UV-Vis fluorescence diagnostics of cataract</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Histology device to reduce cross contamination 
The present invention relates to methods and devices for use in tissue manipulation, particularly to devices for use in preparation of tissue samples for histological or pathological analysis. Embodiments of the invention relate to devices which are adapted to manipulate tissue samples without coming into physical contact with the tissue samples, thereby avoiding issues of cross-contamination. This can be achieved by coating the tip of the devices with a tissue medium which is used to indirectly manipulate the tissue sample, and then release the sample by melting the tissue medium.</gtr:description><gtr:grantRef>MC_PC_12014</gtr:grantRef><gtr:id>0A16CF9D-E27A-4684-B0D9-64066E21D802</gtr:id><gtr:impact>Initiated significant discussions with leading companies</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56df0ae6d49542.58872476</gtr:outcomeId><gtr:patentId>WO2014GB52381 20140804</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Tissue Manipulation Device</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>microRNA biomarkers of drug-induced liver injury</gtr:description><gtr:grantRef>MC_PC_12014</gtr:grantRef><gtr:id>19176439-0A63-45E3-8675-465A205B0902</gtr:id><gtr:impact>supporting development</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>56df0d2b1c6c75.17455071</gtr:outcomeId><gtr:patentId>Serial No. 1512219.5</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>microRNA biomarkers of drug-induced liver injury</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>The product will deliver isolation and lysis of bacteria in a microfluidic system with the same response pattern as conventional micro RNA analysis reporting on suitability on antibiotic therapy choice for incorporation into an established analyser. Final milestone will deliver a comprehensive head to head comparison of known biomarkers of bacterial response, coordinated with potential commercial partner.</gtr:description><gtr:id>56801453-EFD0-4F61-8A0A-C8544B0BCA98</gtr:id><gtr:impact>early in CiC</gtr:impact><gtr:outcomeId>Ka4SwxAJpDP</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CiC EPDD 007 Microsystems for the monitoring of Bacterial Response to Therapy.</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The final product will be an EIS-based assay that has potential to integrate with the M&amp;ouml;lnlycke Health Care-Scotland (MHC-S) handset within 1 hour within 10% of PCR fold change. Results clearly distinguish disease (paracetamol-induced liver injury) from control (paracetamol overdose without any injury). Final milestone will deliver a Test can distinguish healthy from diseased by measuring miR-122 levels in 500 clinical samples. Difference in signal &amp;gt;10 fold. Lower limit of the 95% CI &amp;gt;3 fold.
Initial deliverables of limit of detection and specificity have been achieved</gtr:description><gtr:id>068FEEC5-B7CC-4189-90E6-C05724BFB6B2</gtr:id><gtr:impact>Establishing a strong working relationship with local company M&amp;ouml;lnlycke Health Care-Scotland</gtr:impact><gtr:outcomeId>mvp1jt9fg5v</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CiC EPDD 011 mirPOC - detection of miRNAs indicating drug-induced liver injury at point-of-care.</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The product is designed to provide a device that can direct a laser system for reducing the thickness of the sclera at the back of the eye sufficiently for drugs to permeate into the back of the eye. Final milestone ex-vivo demonstration of viable surgical scheme and proof of concept in terms of enhanced drug transport through sclera. 
The prototype device can deliver a 1-2mm2 array of portals of 100-200um depth that allows increased penetration of large molecule agents.</gtr:description><gtr:id>12F9F6C5-5BA3-49B0-96EE-C2DF8A6E24BC</gtr:id><gtr:impact>We are actively seeking further funding and company spinout options.</gtr:impact><gtr:outcomeId>aXGHJEJMNYb</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CiC EPDD 001 Fibre optic surgical device enabling targeted drug delivery to the posterior eye</gtr:title><gtr:type>Therapeutic Intervention - Surgery</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The product will be system suitable for professional speech therapist to build a personalised voice using any residual patient voice and sampling the voice bank. Final milestones all achieved 
the voice banking tools consists of
- SpeechRecorder (iPhone/iPad)
- Easy-to-use speech recording apps using specially designed texts.
- Voice Cloning Toolkit (Mac)
- Mac software for building speech synthesizers from recorded audio files
- SpeakUnique (iPhone/iPad)
- Communication apps for patients who want to use their own voices
- SAPI5 (Windows)
- Text-to-speech engine that can use patient's voices on Windows-based
AAC devices such as Tobii or DynaVox.
All the above tools have been evaluated and validated by clinicians, speech therapists,
and patients and have been iteratively refined many times.
As planned, our clinicians and speech therapists have successfully recorded, built and
delivered two patient's voices without asking IT researchers or teams. The first patient's
voice have been delivered using iPad mini. The second patient's voice have been
delivered using SAPI5.</gtr:description><gtr:id>97901B35-BB83-411E-BB9D-F0C471E17DE6</gtr:id><gtr:impact>We are currently evaluating the potential to establish a company to control the process of manufacture distribution and license.</gtr:impact><gtr:outcomeId>mjRbCz2MFuj</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CiC EPDD 005 Delivering personalised voices for patients with MND.</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The product already at initial prototype, is a non-contact device for handling histopathology samples that reduces the risk of sample cross-contamination and patient misdiagnosis. Final milestone will deliver data comparing macro, micro and molecular contamination against the current gold standard suitable for publication. 
It has been demonstrated in a blinded trial to remove cross contamination that occurs within 10 manipulations with current optimal process.</gtr:description><gtr:id>65E68FD9-4D45-4B12-A144-F34E271CA678</gtr:id><gtr:impact>The development of this product has help a company to be formed TissuePlex Ltd that is developing a range of improved devices for histology. The team have obtained a TSB grant to develop a water bath product. These innovations will improve processing for current histology and significantly remove the opportunity for error with the evolving field of molecular histology.</gtr:impact><gtr:outcomeId>CPAkJELb2zn</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CiC EPDD 008 Tissuestik</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The product will be a sample preparation micro fluidic device that will allow rapid separation and concentration of foetal DNA suitable for non-invasive prenatal diagnosis of foetal disease and treatment needs such as for rhesus factor incompatibility. Final milestone will demonstrate if enough cffDNA can be concentrated from maternal blood to make this process useful for NIPD in the first trimester of pregnancy.</gtr:description><gtr:id>0EF7D139-E039-4F05-B110-577F3079F043</gtr:id><gtr:impact>Too early in CiC.
worth noting that following an oral presentation considerable interest has been generated and discussions with two key companies have been initiated.</gtr:impact><gtr:outcomeId>ZUAGTv5hGbY</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CiC EPDD 004 fetaSAFE - Microfluidic concentration of circulating foetal nucleic acids from maternal blood.</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>An Instrument for the Early Diagnosis of Cataracts. The product is designed to replace the slit detector with an monitoring of Trytophan Fluorescence using LED for both diagnosis and as a research tool enabling the assessment in trials of pharmaceutical interventions (e.g. N- Acetyl Carnosine as published) as well as the femtosecond laser potential therapy pathway. Final milestone involves building a research prototype machine.</gtr:description><gtr:id>5840818C-7421-4942-B10A-D144B4331617</gtr:id><gtr:impact>too early in project. 
Supporting grant application.</gtr:impact><gtr:outcomeId>ZrPu81tDcke</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CiC EPDD 002 CATANOSTICS</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The product will be a compound suitable for facilitating the analytical detection of estrogens in tissue samples. Final milestone will demonstrate FTICR-MS can detect reproducibly androgens and estrogens in breast tumour tissue with RSD&amp;lt;20% and a signal to noise for quantitation &amp;gt;3 and the result can be reported as a quantitative outcome suitable for diagnosis and clinical trials.</gtr:description><gtr:id>F5C9896A-2231-46C3-BBDE-4AE72B5C19BB</gtr:id><gtr:impact>too early in CiC</gtr:impact><gtr:outcomeId>Xgo5afLeUkD</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CiC EPDD 003 Developing Mass Spectrometric Imaging of Estrogens in Hormone Sensitive Tumours of the Breast.</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The product will assist difficult transplants (when cirrhosis is present) when separating the liver form the cava is even more taxing and dangerous and may add several hours to an operation which already takes between 6-10 hours. Reducing the risk of catastrophic bleeding and need for upwards of 40 units of blood, additional clotting factors and a prolonged stay in intensive care would be expected for those patients who survive (&amp;pound;1000 per day in ITU). Final milestone will deliver a device fully evaluated in a large animal model. 
The first prototype has been evaluated ex vivo and in vivo evaluations are due to take place as soon as the license is secured and the surgical training is complete.</gtr:description><gtr:id>C7A841C1-DEE7-4B52-94DB-0E9293A04CAC</gtr:id><gtr:impact>The Investigator has received an award from the CSO to provide one day per week to focus on innovation. His next product idea won the local innovation competition and was kick-started with the &amp;pound;15,000 prize.</gtr:impact><gtr:outcomeId>mUgc1okTacW</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CiC EPDD 009 Development of a hepatic vascular catheter to improve outcomes during liver transplantation.</gtr:title><gtr:type>Therapeutic Intervention - Medical Devices</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The product will be the operative component in a device that separates cells prior to their administration to patients (or other uses) to eliminate dead cells with inhibitory, toxic and proinflammatory properties. Final milestone will deliver a design with potential to be CE marked, manufactured to GMP and works when sterilized that can robustly remove dead cells with the same levels of proficiency (minimally 90% as proficient) as the prototype with at least two cell types with retention of sterility throughout sorting process.</gtr:description><gtr:id>048FE2FE-8680-4B3F-A756-C3536A5E9801</gtr:id><gtr:impact>Early in CiC</gtr:impact><gtr:outcomeId>ihuLSuuMazW</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CiC EPDD 006 A Device for Label-Free Purification of Viable Cells for Therapy.</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The product is a portable oxygenation system that would support with a portable extracorporeal membrane oxygenation ECMO for organ recovery from donors after circulatory death is performed. Fewer organs are recovered compared to brain-dead donors (1.7 vs 3.2 organs/donor) and transplantation is associated with more complications. Final milestone will deliver a product will be tested in a head to head comparison with the current equipment used in clinicalractice and will be equivalent capabilities but portable.</gtr:description><gtr:id>8CE0C5E7-C06C-406A-A468-D59C8AFA2239</gtr:id><gtr:impact>early in CiC</gtr:impact><gtr:outcomeId>Lh2nWkwgAfN</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CiC EPDD 010 A portable integrated device for organ recovery from donors after circulatory death under normothermic conditions.</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A reagent was developed that can stabilise and extract bacterial RNA from whole blood. A microfluidic device was developed that could process this whole blood in this reagent to prepare samples suitable for bacterial RNA analysis.</gtr:description><gtr:id>0BB4D6B5-B7EC-4B70-A3ED-FAC87480AB8B</gtr:id><gtr:impact>This method is suitable for use in a determination of bacterial RNA in a point of care device that should be able to rapidly report on the early outcome of antibiotic therapy.</gtr:impact><gtr:outcomeId>545a7e8b1b4c42.91407723</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CiC MicroBRT</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Viable and non-viable cells can also be separated by manipulating their movement in non-uniform electric fields (dielectrophoresis, DEP). This is because, when cells die, their size, plasma-membrane capacitance and ionic porosity change, resulting in changes in the electric field frequencies at which the dielectric properties of the cells exactly match those of the surrounding medium (the so-called DEP crossover frequency or Fxo). By using microelectrodes energised with AC voltages in a defined range of frequencies, distinct Fxos can be established for viable, as compared with non-viable, cells. For example, viable cells typically exhibit a dynamic distribution of DEP Fxos ranging from 50-250 kHz while non-viable cells progress from the upper value of this range beyond 400 kHz as apoptosis progresses1. Such differences in DEP responses can be used to sort cells with high efficiency. Indeed, different cell types of similar size (namely myoblasts and fibroblasts) can be efficiently sorted in this way (to 98% purity at sorting rates of around 2x105 cells per hour) because of differences in their plasma membrane capacitance2. Since differences in DEP responses between viable and non-viable cells are more substantial, we anticipate that increased flow rates can be used to sort viable from non-viable cells more rapidly and that, in combination with 1g sedimentation prior to DEP sorting, rates of viable-cell purification of 106-109 cells per hour can be achieved.</gtr:description><gtr:id>4B9FB9B1-6773-433C-B8C2-5F23BA8B279A</gtr:id><gtr:impact>Investigator has completed a stage 1 H2020 application which could be relevant feedback since, if successful it will extend what we learned about DEP during the CiC (and without the CiC we wouldn't have made the application!). I am leading the application on behalf of UEDIN and the consortium is called CRYOREV (16 partners, a mixture of academic and commercial institutions) and the call is Tools and technologies for advanced therapies PHC-16-2015. The project is entitled Automated revival and monitoring of cryopreserved cells for regenerative therapies, with a DEP cytometer being developed to be used on the monitoring side (one of the work packages). If successful it will provide funding of almost 6 million Euros
Dielectrophoresis has the potential to be applied to all types of cell for assessment of viability - for example for pancreatic islet viability analysis. Determination of islet viability prior to transplantation is critical but current techniques are sub-optimal. Based on findings from this CiC project, funding was secured from the EPSRC to investigate translating this technology to pancreatic islet viability testing alongside use of a novel technique for pancreatic islet isolation. The EPSRC project is a collaboration between The Universities of Edinburgh, Newcastle and Heriot-Watt. We also secured a small equipment grant from the Moray Endowment fund to purchase specialised equipment for the latter part of the CiC project.</gtr:impact><gtr:outcomeId>545a7b94384b56.50956157</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>CiC A device for label free purification of viable cells for therapy</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A6635956-1311-4E92-9C72-CCB34CF6D20B</gtr:id><gtr:title>MEDICAL LASER APPLICATIONS AND LASER-TISSUE INTERACTIONS</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c774fc7d79e67fe70a15705f4ea99eb2"><gtr:id>c774fc7d79e67fe70a15705f4ea99eb2</gtr:id><gtr:otherNames>Gora, W. S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56df03ba43e714.74480449</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37D857D5-5832-49C6-8FA5-BD0156F0B835</gtr:id><gtr:title>Spatial Localization and Quantitation of Androgens in Mouse Testis by Mass Spectrometry Imaging.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a580c96c271ad5a8eeeb09b3ad2ccae3"><gtr:id>a580c96c271ad5a8eeeb09b3ad2ccae3</gtr:id><gtr:otherNames>Cobice DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn><gtr:outcomeId>585d35f555f882.74335529</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A873E0F-C6C4-4C2D-8252-0387A84D5A96</gtr:id><gtr:title>Mass spectrometry imaging for dissecting steroid intracrinology within target tissues.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a580c96c271ad5a8eeeb09b3ad2ccae3"><gtr:id>a580c96c271ad5a8eeeb09b3ad2ccae3</gtr:id><gtr:otherNames>Cobice DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn><gtr:outcomeId>5a79b51492dbf9.63407832</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56CF317A-1F69-496D-96B4-AA8A1601AF58</gtr:id><gtr:title>Picosecond laser ablation of porcine sclera</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/321d559ba1409d3f1478fb82ad55dfe3"><gtr:id>321d559ba1409d3f1478fb82ad55dfe3</gtr:id><gtr:otherNames>G?ra W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>58c2de764d5397.20839204</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4079180-DD2D-4A1D-B2DA-8A5E46AE60B7</gtr:id><gtr:title>Transformative biomarkers for drug-induced liver injury: are we there yet?</gtr:title><gtr:parentPublicationTitle>Biomarkers in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e875e1050196c8d029bc61e171597736"><gtr:id>e875e1050196c8d029bc61e171597736</gtr:id><gtr:otherNames>Antoine DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1752-0363</gtr:issn><gtr:outcomeId>58c6b3ff86c866.94848035</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DC2C69C-099C-4B9D-A411-05DD474F4E71</gtr:id><gtr:title>Reconstructing Voices within the Multiple-Average-Voice-Model framework.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d877d7023152243e3f4a6057fc68fda"><gtr:id>7d877d7023152243e3f4a6057fc68fda</gtr:id><gtr:otherNames> Lanchantin, P;</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56df09de088035.80341222</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C0B7859-3865-4704-B8A6-C2625CEEB173</gtr:id><gtr:title>2.5 Direct Fetal DNA Fraction Enrichment Using Microfluidic Sample Preparation of Maternal Blood for Non-Invasive Prenatal Testing</gtr:title><gtr:parentPublicationTitle>Archives of Disease in Childhood - Fetal and Neonatal Edition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/964739303f296db2ee0f2c84004304bc"><gtr:id>964739303f296db2ee0f2c84004304bc</gtr:id><gtr:otherNames>Kersaudy-Kerhoas M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56def1b35cb774.56359714</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>558324FB-BF16-4798-A4EE-392C0FB4B53B</gtr:id><gtr:title>Recent advances in biomarkers and therapeutic interventions for hepatic drug safety - false dawn or new horizon?</gtr:title><gtr:parentPublicationTitle>Expert opinion on drug safety</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/024af92bcbdbce679fd54c84aaf18417"><gtr:id>024af92bcbdbce679fd54c84aaf18417</gtr:id><gtr:otherNames>Clarke JI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-0338</gtr:issn><gtr:outcomeId>58c6b3ff580ad5.14066703</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3AAF8CD9-3867-424D-87D7-D3B46B5990E1</gtr:id><gtr:title>Gas chromatography tandem mass spectrometry offers advantages for urinary steroids analysis.</gtr:title><gtr:parentPublicationTitle>Analytical biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4de7736368dfe170086d5d398489a463"><gtr:id>4de7736368dfe170086d5d398489a463</gtr:id><gtr:otherNames>Homer N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-2697</gtr:issn><gtr:outcomeId>5a9d63a474ad42.54537537</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>373A090F-6127-4746-8172-4956EA746C52</gtr:id><gtr:title>Impact of microfluidic processing on bacterial ribonucleic acid expression.</gtr:title><gtr:parentPublicationTitle>Biomicrofluidics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbb0dda652bc142cb8a321421f148f06"><gtr:id>bbb0dda652bc142cb8a321421f148f06</gtr:id><gtr:otherNames>Gandi SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-1058</gtr:issn><gtr:outcomeId>56def3ff99b811.80943886</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB88E892-79E2-4CA4-9C2F-E92C6FFD50D7</gtr:id><gtr:title>Future technology insight: mass spectrometry imaging as a tool in drug research and development.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a580c96c271ad5a8eeeb09b3ad2ccae3"><gtr:id>a580c96c271ad5a8eeeb09b3ad2ccae3</gtr:id><gtr:otherNames>Cobice DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>5a79b5640f7176.56492952</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_12014</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>